Felipe Javier Chaves
Instituto de Salud Carlos III
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Felipe Javier Chaves.
Scientific Reports | 2015
M. Mar Rodríguez; Daniel R. Perez; Felipe Javier Chaves; Eduardo Esteve; Pablo Marin-Garcia; Joan Vendrell; Mariona Jové; Reinald Pamplona; Wifredo Ricart; Manuel Portero-Otin; Matilde R. Chacón; José Manuel Fernández Real
The human intestine is home to a diverse range of bacterial and fungal species, forming an ecological community that contributes to normal physiology and disease susceptibility. Here, the fungal microbiota (mycobiome) in obese and non-obese subjects was characterized using Internal Transcribed Spacer (ITS)-based sequencing. The results demonstrate that obese patients could be discriminated by their specific fungal composition, which also distinguished metabolically “healthy” from “unhealthy” obesity. Clusters according to genus abundance co-segregated with body fatness, fasting triglycerides and HDL-cholesterol. A preliminary link to metabolites such as hexadecanedioic acid, caproic acid and N-acetyl-L-glutamic acid was also found. Mucor racemosus and M. fuscus were the species more represented in non-obese subjects compared to obese counterparts. Interestingly, the decreased relative abundance of the Mucor genus in obese subjects was reversible upon weight loss. Collectively, these findings suggest that manipulation of gut mycobiome communities might be a novel target in the treatment of obesity.
Journal of Translational Medicine | 2012
Carmen Ivorra; Consuelo Garcia-Vicent; Felipe Javier Chaves; Daniel Monleón; José Manuel Morales; Empar Lurbe
BackgroundLow birth weight has been linked to an increased risk to develop obesity, type 2 diabetes, and hypertension in adult life, although the mechanisms underlying the association are not well understood. The objective was to determine whether the metabolomic profile of plasma from umbilical cord differs between low and normal birth weight newborns.MethodsFifty healthy pregnant women and their infants were selected. The eligibility criteria were being born at term and having a normal pregnancy. Pairs were grouped according to their birth weight: low birth weight (LBW, birth weight < 10th percentile, n = 20) and control (control, birth weight between the 75th-90th percentiles, n = 30). Nuclear Magnetic Resonance (NMR) was used to generate metabolic fingerprints of umbilical cord plasma samples. Simultaneously, the metabolomic profiles of the mothers were analysed. The resulting data were subjected to chemometric, principal component and partial least squares discriminant analyses.ResultsUmbilical cord plasma from LBW and control newborns displayed a clearly differentiated metabolic profile. Seven metabolites were identified that discriminate the LBW from the control group. LBW newborns had lower levels of choline, proline, glutamine, alanine and glucose than did the control newborns, while plasma levels of phenylalanine and citrulline were higher in LBW newborns (p < 0.05). No significant differences were found between the two groups of mothers.ConclusionsLow birth weight newborns display a differential metabolomic profile than those of normal birth weight, a finding not present in the mothers. The meaning and the potential utility of the findings as biomarkers of risk need to be addressed in future studies.
PLOS ONE | 2015
Javier Perez-Hernandez; Maria J. Forner; Carolina Pinto; Felipe Javier Chaves; R. Cortés; Josep Redon
There is increased interest in using microRNAs (miRNAs) as biomarkers in different diseases. Present in body fluids, it is controversial whether or not they are mainly enclosed in exosomes, thus we studied if urinary miRNAs are concentrated inside exosomes and if the presence of systemic lupus erythematosus with or without lupus nephritis modifies their distribution pattern. We quantified specific miRNAs in urine of patients with systemic lupus erythematosus (n = 38) and healthy controls (n = 12) by quantitative reverse-transcription PCR in cell-free urine, exosome-depleted supernatant and exosome pellet obtained by ultracentrifugation. In control group, miR-335* and miR-302d were consistently higher in exosomes than in exosome-depleted supernatant, and miR-200c and miR-146a were higher in cell-free fraction. In lupus patients, all urinary miRNAs tested were mainly in exosomes with lower levels outside them (p<0.05 and p<0.01, respectively). This pattern is especially relevant in patients with active lupus nephritis compared to the control group or to the SLE patients in absence of lupus nephritis, with miR-146a being the most augmented (100-fold change, p<0.001). Among the exosomal miRNAs tested, only the miR-146a discriminates the presence of active lupus nephritis. In conclusion, urinary miRNAs are contained primarily in exosomes in systemic lupus erythematosus, and the main increment was found in the presence of active lupus nephritis. These findings underscore the attractiveness of exosomal miRNAs in urine, a non-invasive method, as potential renal disease markers.
American Journal of Hypertension | 2001
Felipe Javier Chaves; Jose Maria Pascual; Eduardo Rovira; Maria E. Armengod; Josep Redon
The objective of this study was to analyze the relationship of polymorphisms of the angiotensin II AT1 receptor gene with microalbuminuria in a group of young adults with essential hypertension. Essential hypertensives, less than 50 years old, never previously treated with antihypertensive drugs, and in absence of diabetes mellitus were included. Office blood pressure (BP), 24-h ambulatory BP monitoring, urinary albumin excretion (UAE) measurements, and DNA analysis were performed. Polymorphisms of the angiotensin II AT1-receptor gene (A1166C and C573T) were studied by polymerase chain reaction and single-strand conformation polymorphism techniques. One hundred eighty-three patients, 49 (27%) microalbuminurics, were included. Office and ambulatory BP values were significantly higher in the microalbuminuria group. No differences in the presence of microalbuminuria were observed among the genotypes of either A1166C or C573T polymorphisms of the angiotensin II receptor AT1 gene, or in the allele frequency of the A1166C or the C573T polymorphism. LogUAE was significantly different among genotypes of the C573T polymorphism [CC 1.30(1.15-1.45), CT 1.14(1.00-1.28), and TT 0.94(0.68-1.20), P < .05]. Both office and ambulatory blood pressure and the TT/C573T genotype were independently related to logUAE, and, at the same BP values, UAE was lower in subjects with this genotype. We have found that the C573T polymorphism is on linkage disequilibrium with A1166C, as the 573T allele is closely linked to the presence of the 1166A allele, but not vice versa. Haplotype analysis among subjects with the AA genotype for the A1166C polymorphism confirms the influence of the TT genotype of the C573T polymorphism on the UAE in hypertensives. The C573T polymorphism of the angiotensin II receptor AT1 gene seems to be a genetic protective factor for UAE in a population of essential hypertensives.
PLOS ONE | 2012
Maria L. Mansego; Fernando Martinez; Maria Teresa Martínez-Larrad; Carina Zabena; Gemma Rojo; Sonsoles Morcillo; Federico Soriguer; Juan Carlos Martín-Escudero; Manuel Serrano-Ríos; Josep Redon; Felipe Javier Chaves
Summary The main objective was to evaluate the association between SNPs and haplotypes of the FABP1-4 genes and type 2 diabetes, as well as its interaction with fat intake, in one general Spanish population. The association was replicated in a second population in which HOMA index was also evaluated. Methods 1217 unrelated individuals were selected from a population-based study [Hortega study: 605 women; mean age 54 y; 7.8% with type 2 diabetes]. The replication population included 805 subjects from Segovia, a neighboring region of Spain (446 females; mean age 52 y; 10.3% with type 2 diabetes). DM2 mellitus was defined in a similar way in both studies. Fifteen SNPs previously associated with metabolic traits or with potential influence in the gene expression within the FABP1-4 genes were genotyped with SNPlex and tested. Age, sex and BMI were used as covariates in the logistic regression model. Results One polymorphism (rs2197076) and two haplotypes of the FABP-1 showed a strong association with the risk of DM2 in the original population. This association was further confirmed in the second population as well as in the pooled sample. None of the other analyzed variants in FABP2, FABP3 and FABP4 genes were associated. There was not a formal interaction between rs2197076 and fat intake. A significant association between the rs2197076 and the haplotypes of the FABP1 and HOMA-IR was also present in the replication population. Conclusions The study supports the role of common variants of the FABP-1 gene in the development of type 2 diabetes in Caucasians.
Journal of Hypertension | 2011
Maria L. Mansego; Griselda De Marco Solar; Mónica Pineda Alonso; Fernando Martinez; Guillermo T. Sáez; Juan Carlos Martín Escudero; Josep Redon; Felipe Javier Chaves
Objective To assess the association of single-nucleotide polymorphisms (SNPs) in genes codifying for antioxidant enzymes to blood pressure (BP) values and risk of hypertension. Methods Population-based study including 1388 participants (704 women) older than 18 years in which 300 were untreated hypertensive patients. In 335 untreated hypertensive patients referred to one hypertension clinic, the study was replicated. Thirty-five SNP throughout 13 genes were analyzed using SNPlex. In a subgroup of hypertensive patients, the amount of 8-oxo-deoxyguanosine and GPX activity levels was measured in mononuclear cells. Results In the general population, genotypes with the G allele of the c.172G>A polymorphism in the SOD3 gene and those with the T allele of the c.-20C>T polymorphism in the CAT gene were associated with significant lower values of BP. Likewise, these genotypes were associated with less risk for hypertension after adjusting for confounder variables. Haplotypes in both genes increased the strength of associations. In the hypertensive patients, the same alleles of the two polymorphisms were associated with lower BP values too. In addition, two others, the CT-TT genotypes of the c.*891C>T polymorphism in the GPX1 gene and the CT-CC genotypes of the c.-793T>C polymorphism of the TXN gene were also significantly associated to lower BP values. Furthermore, the CC genotype of the c.*891C>T polymorphism in the GPX1 gene was associated with higher values of 8-oxo-dG and GPX activity levels as compared to those for the CT-TT genotype. Conclusions The results of the present study support the influence of antioxidant enzyme genes in BP values and hypertension risk.
European Journal of Clinical Investigation | 2001
Felipe Javier Chaves; J.T. Real; Ana-Barbara García-García; O. Puig; Jose M. Ordovas; J. Ascaso; R. Carmena; M. E. Armengod
Background Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the low‐density lipoprotein receptor (LDLR) gene. To date, there has not been a systematic survey of the frequency of gross mutations in the LDLR gene in the Spanish population. The objective of our study was to investigate large rearrangements in the Spanish FH population and the relation between the kind of large rearrangement and the phenotype in carrier families.
Hypertension | 2000
Josep Redon; Felipe Javier Chaves; Youlian Liao; Jose Maria Pascual; Eduardo Rovira; Maria E. Armengod; Richard S. Cooper
The objective of the present study was to analyze the influence of the I/D polymorphism of the ACE gene on the outcome of microalbuminuria in essential hypertensive patients who were receiving antihypertensive treatment. One hundred thirty-six essential hypertensive patients who were <50 years old and had never previously received treatment with antihypertensive drugs were included in the study. During a 3-year period, patients received nonpharmacological treatment consisting of moderate salt restriction and a low-calorie diet they were obese, with or without a regimen of antihypertensive drugs based on beta-blockers or ACE inhibitors. Hydrochlorothiazide was added when necessary to maintain the blood pressure goal of <135/85 mm Hg. At the beginning of the study and at yearly intervals, systolic and diastolic blood pressures (SBP and DBP, respectively), 24-hour urinary albumin excretion (UAE), renal function, and biochemical profile measurements were made. The insertion/deletion (I/D) polymorphism of the ACE gene was determined through the use of polymerase chain reaction. The variables used in the statistical analysis were the measurements at the start of the study and the increase or decrease detected during the follow-up, estimated as individual specific regression line slope values. At baseline, no differences in blood pressure or UAE values were observed among genotypes. Likewise, the genotype or allele frequency was not significantly different between normoalbuminurics and microalbuminurics. After the 3 treatment years, significant reductions in SBP, DBP, and UAE were found (SBP 151.6+/-17.3 reduced to 137.2+/-14.3 mm Hg, P<0.001; DBP 96.6+/-8.9 reduced to 84.5+/-9.8 mm Hg, P<0.001; UAE 36.7+/-71.5 reduced to 28.3+/-78.6 mg/24 h, P<0. 05). The slopes of these parameters over time did not differ significantly among genotypes. The slope of SBP was the main factor related to the slope of logUAE (P<0.003). A significant positive correlation coefficient between the SBP and logUAE slopes was observed for the DD patients (r=0.57, P<0.0001) but was absent in patients carrying the I allele (II r=-0.03, P=NS; I/D r=0.01, P=NS). Follow-up studies should be used to achieve a better understanding of the impact of candidate gene polymorphisms on the development of hypertension-induced organ damage. Assessment of the I/D polymorphism of the ACE gene may identify subjects who require a greatly lowered blood pressure to prevent organ damage and to reduce hypertension-associated complications and death.
European Journal of Clinical Investigation | 2010
J.T. Real; Sergio Martinez-Hervas; Ana-Barbara García-García; Miguel Civera; Federico V. Pallardó; J. Ascaso; J.R. Viña; Felipe Javier Chaves; R. Carmena
Eur J Clin Invest 2010; 40 (2): 89–94
Pharmacogenetics and Genomics | 2005
Ana Barbara Garcia-Garcia; Cintia González; José T. Real; José Javier Martín de Llano; Veronica Gonzalez-Albert; Miguel Civera; Felipe Javier Chaves; Juan F. Ascaso; Rafael Carmena
Familial hypercholesterolaemia (FH) is an autosomal dominant disease characterized by elevated levels of low-density lipoprotein-cholesterol (LDL-C). Phenotypic expression is highly variable, being influenced by diet, age, gender, body mass index, apolipoprotein E genotype and type of LDL-receptor gene mutation. Microsomal triglyceride (TG) transfer protein (MTP) is a protein involved in lipid metabolism. Polymorphism MTP −493 GT has been shown to modulate lipid levels in several populations. To analyse the effect of this polymorphism in the lipid phenotype expression of FH and treatment response, we studied a sample of 222 Spanish FH patients, of whom 147 were studied before and after treatment with 20 mg of atorvastatin daily during 6 weeks. The variant was analysed by polymerase chain reaction amplification and single-strand confirmation polymorphism. Treatment reduced LDL-C, total cholesterol and TGs. Baseline fasting TGs and very-low-density lipoprotein cholesterol levels were lower in female T allele carriers (TG: 111±51 mg/dl GG, 89±35 mg/dl GT, 83±26 mg/dl TT, P=0.022; very-low-density lipoprotein cholesterol: 24±13 mg/dl GG, 16±5 mg/dl GT, 17±5 mg/dl TT, P=0.018). Triglyceride response to atorvastatin was modulated by this polymorphism in men (P=0.009), but not in women, although differences between genotypes were maintained after treatment. In conclusion, the MTP −493 GT polymorphism modulates pre- and post-treatment plasma TG values of FH in Spanish subjects in a gender-specific way. Other environmental and genetic factors likely also modulate this response.